ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$7.98
+0.88%0
Insider buys (3m)
1
Insider sells (3m)
-$175.2K
Net value (3m)
+55.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | Stewart Richard Alistair · director | Sale | 20,626 | $8.49 |
| Jul 29, 2026 | Royston Aaron · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Waldman Reid Alexander · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Stewart Richard Alistair · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Martin Christopher Nathan · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Stewart Richard Alistair · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Sellig Thomas · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Farrow Jeffrey S · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Farrow Jeffrey S · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Phelan Nancy R. · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Phelan Nancy R. · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Martin Christopher Nathan · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Sellig Thomas · director | A-Award | 25,000 | $6.18 |
| Jul 29, 2026 | Royston Aaron · director | A-Award | 16,700 | $0.00 |
| Jul 29, 2026 | Waldman Reid Alexander · director | A-Award | 25,000 | $6.18 |
| Jun 2, 2026 | Waldman Reid Alexander · director | A-Award | 47,250 | $5.24 |
| Jun 2, 2026 | Farrow Jeffrey S · director | A-Award | 47,250 | $5.24 |
| May 13, 2026 | Martin Christopher Nathan · director | A-Award | 47,250 | $5.59 |
| Apr 21, 2026 | Goldberg Andrew D. · director, officer: CEO and President | A-Award | 1,800,965 | $0.00 |
| Apr 21, 2026 | Goldberg Andrew D. · director, officer: CEO and President | A-Award | 11,706,270 | $0.00 |
| Apr 21, 2026 | Goldberg Andrew D. · director, officer: CEO and President | A-Award | 3,601,929 | $4.25 |
| Jan 30, 2026 | Xinos Jaime · officer: Chief Commercial Officer | A-Award | 180,000 | $4.36 |
| Jan 30, 2026 | Rubinstein Mark Lawrence · officer: Chief Medical Officer | A-Award | 180,000 | $4.36 |
| Jan 30, 2026 | Wan Jerry · officer: Principal Accounting Officer | A-Award | 70,300 | $4.36 |
| Jan 30, 2026 | Stewart Richard Alistair · director, officer: Chief Executive Officer | A-Award | 645,000 | $4.36 |
| Jan 30, 2026 | Oki Mark K · officer: Chief Financial Officer | A-Award | 180,000 | $4.36 |
| Jan 30, 2026 | Donnelly Craig · officer: Chief Operations Officer | A-Award | 180,000 | $4.36 |
| Dec 8, 2025 | Atkisson Erik · officer: Chief Legal Officer | A-Award | 250,000 | $4.78 |
| Oct 3, 2025 | Donnelly Craig · officer: Chief Operations Officer | A-Award | 50,000 | $3.10 |
| Sep 22, 2025 | Stewart Richard Alistair · director, officer: Chief Executive Officer | Sale | 129,501 | $2.92 |
Institutional positioning
13F filings over the trailing two quarters
New 64Increased 58Reduced 38Sold out 17
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | New Position | 7,614,836 | Aug 14, 2026 |
| TPG GP A, LLC | New Position | 6,877,580 | Aug 14, 2026 |
| venBio Partners LLC | New Position | 5,914,720 | Aug 14, 2026 |
| Logos Global Management LP | New Position | 5,425,000 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 5,272,017 | Aug 7, 2026 |
| FRANKLIN RESOURCES INC | Increased | 4,953,220 | Aug 13, 2026 |
| Paradigm Biocapital Advisors LP | New Position | 4,951,856 | Aug 14, 2026 |
| FRANKLIN RESOURCES INC | Unchanged | 4,369,193 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 4,140,812 | Aug 13, 2026 |
| Propel Bio Management, LLC | Increased | 4,034,018 | Aug 13, 2026 |
| PROPEL BIO MANAGEMENT, LLC | Unchanged | 3,786,425 | May 14, 2026 |
| MARSHALL WACE, LLP | Increased | 3,770,313 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 2,945,526 | Aug 7, 2026 |
| Jupiter Topco LLC | New Position | 2,751,032 | Aug 14, 2026 |
| Vivo Capital, LLC | New Position | 2,751,032 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 21, 2026